jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
Journal of Young PharmacistsNOW IN
Article

EGFR-mTOR siRNA Loaded Immumonanoparticles for Targeted Chemotherapy of Triple Negative Breast Cancer

Krishnan Shalini1,2, Rajavel Varatharajan3★, Hamid Shahrul2★, Palanimuthu Vasanth Raj4, Venugopal Vijayan5★ Corresponding author

  1. 1Biochemistry Unit, Faculty of Medicine, AIMST University, Semeling, Bedong, Kedah Darul Aman, MALAYSIA.
  2. 2Department of Biomedical Science, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang, MALAYSIA.
  3. 3Faculty of Pharmacy, Pharmacology, Toxicology and Basic Health Sciences Unit AIMST University, Semeling, Bedong, Kedah Darul Aman, MALAYSIA.
  4. 4School of Pharmacy, Medical Biology Centre, Queen’s University of Belfast, Lisburn Road, Belfast, Northern Ireland, UNITED KINGDOM.
  5. 5School of Pharmacy, Sri Balaji Vidyapeeth University, Pillayarkuppam, Puducherry, INDIA.

CORRESPONDENCE

Rajavel Varatharajan

Faculty of Pharmacy, Pharmacology, Toxicology and Basic Health Sciences Unit AIMST University, Semeling, Bedong, Kedah Darul Aman, MALAYSIA.

varadharajeen@gmail.com

Received: 06-08-2024; Revised: 20-08-2024; Accepted: 03-09-2024.

Volume 16, Issue 4 · pp. 714–724 · PUBLISHED · DOI: 10.5530/jyp.2024.16.91

View on JYP original site ↗

ABSTRACT

Background:Triple-Negative Breast Cancer (TNBC) presents a significant clinical challenge due to its aggressive nature and limited therapeutic options. A promising treatment strategy involves targeting Epidermal Growth Factor Receptor (EGFR) signaling and PI3K/Akt/mTOR pathways that are hyperactivated in many breast carcinomas. In our study, we aimed to develop a drug delivery system utilizing Paclitaxel (PTX) bio-conjugated with mammalian Target of Rapamycin (mTOR) small interfering RNA (siRNA) nanoparticles, which were further conjugated with EGFR to specifically target TNBC cells. Materials and Methods:The nanoparticles were synthesized using a precipitation method followed by solvent evaporation. They were characterized for size, shape, entrapment efficiency, and drug release kinetics. Additionally, we assessed their cytotoxicity, migration assay, and siRNA binding efficiency using gel retardation. Results:The results showed that the EGFR-mTOR siRNA-loaded immuno nanoparticles had a mean size of 186.6 nm with a zeta potential of 46.57±12.3 mV and an entrapment efficiency of 76.3±3.6%. Gel retardation assays confirmed the integrity of mTOR post-conjugation with mTOR immuno nanoparticles. The anticancer activity of mTOR immuno nanoparticles was evaluated using MDA-MB231 and MDA-MB468 TNBC cell lines, demonstrating significant cytotoxicity. The antibody-conjugated immuno nanoparticles showed enhanced targeting specificity and efficacy against TNBC cells. Conclusion:In summary, mTOR immuno nanoparticles exhibit potential as a targeted therapeutic strategy for TNBC, providing enhanced effectiveness while reducing the adverse effects associated with conventional chemotherapy. This novel drug delivery system's potential to improve therapeutic efficacy and mitigate systemic toxicity underscores its translational relevance in cancer treatment.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Shalini, K., Varatharajan, R., Shahrul, H., Raj, P. V., & Vijayan, V. (). EGFR-mTOR siRNA Loaded Immumonanoparticles for Targeted Chemotherapy of Triple Negative Breast Cancer. Journal of Young Pharmacists, 16(4), 714–724. https://doi.org/10.5530/jyp.2024.16.91